Myths vs. Facts: Getting Breyanzi (lisocabtagene maraleucel) Covered by Aetna (CVS Health) in Florida
Quick Answer: Aetna (CVS Health) requires prior authorization for Breyanzi (lisocabtagene maraleucel) under Clinical Policy Bulletin #986, covering FDA-approved B-cell lymphoma indications for patients ≥18 with ECOG ≤2 after documented treatment failures. Submit PA via Availity portal or fax 1-877-269-9916 with complete clinical documentation. If denied, file internal appeal within